European Journal of Cardio-Thoracic Surgery, Vol 10, 1-5, Copyright © 1996 by European Association for Cardio-thoracic Surgery
Graft coronary vasculopathy in cardiac transplantation--evaluation of risk factors by multivariate analysis
T Wahlers, HG Fieguth, M Jurmann, J Albes, B Hausen, S Demertzis, HJ Schafers, P Oppelt, A Mugge and HG Borst
Department of Cardiothoracic Surgery, Hannover Medical School, Germany.
The development of coronary vasculopathy is the main determinant of
long-term survival in cardiac transplantation. The identification of risk
factors, therefore, seems necessary in order to identify possible treatment
strategies. Ninety-five out of 397 patients, undergoing orthotopic cardiac
transplantation from 10/1985 to 10/1992 were evaluated retrospectively on
the basis of perioperative and postoperative variables including age, sex,
diagnosis, previous operations, renal function, cholesterol levels, dosage
of immunosuppressive drugs (cyclosporin A, azathioprine, steroids),
incidence of rejection, treatment with calcium channel blockers at 3, 6,
12, and 18 months postoperatively. Coronary vasculopathy was assessed by
annual angiography at 1 and 2 years postoperatively. After univariate
analysis, data were evaluated by stepwise multiple logistic regression
analysis. Coronary vasculopathy was assessed in 15 patients at 1 (16%), and
in 23 patients (24%) at 2, years. On multivariate analysis, previous
operations and the incidence of rejections were identified as significant
risk factors (P < 0.05), whereas the underlying diagnosis had borderline
significance (P = 0.058) for the development of graft coronary
vasculopathy. In contrast, all other variables were not significant in our
subset of patients investigated. We therefore conclude that the development
of coronary vasculopathy in cardiac transplant patients mainly depends on
the rejection process itself, aside from patient-dependent factors.
Therapeutic measures, such as the administration of calcium channel
blockers and regulation of lipid disorders, may therefore only reduce the
progress of native atherosclerotic disease in the posttransplant setting.